Mankind Pharma

Mankind Pharma Liabilities

The The Liabilities of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 115.18 B INR. In the previous year, The Liabilities was 131.91 B INR — a change of -12.68% (lower).

Liabilities

115.18 BINR

YoY

-12.68%

Last updated:

In 2026, Mankind Pharma's total liabilities amounted to 115.18 B INR, a -12.68% difference from the 131.91 B INR total liabilities in the previous year.

The Mankind Pharma Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
11.31 B INR
Jan 1, 2020
14.02 B INR
Jan 1, 2021
15.10 B INR
Jan 1, 2022
28.31 B INR
Jan 1, 2023
20.67 B INR
Jan 1, 2024
23.87 B INR
Jan 1, 2025
131.91 B INR
Jan 1, 2026
115.18 B INR
The Mankind Pharma Liabilities history
YEARLiabilitiesYoY
115.18 BINR-12.68%
131.91 BINR+452.53%
23.87 BINR+15.52%
20.67 BINR-27.01%
28.31 BINR+87.54%
15.10 BINR+7.71%
14.02 BINR+23.96%
11.31 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Mankind Pharma's Liabilities

Mankind Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Mankind Pharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Mankind Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Mankind Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Mankind Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Mankind Pharma stock

The Liabilities of Mankind Pharma is 115.18 B INR in 2026.

The Liabilities of Mankind Pharma changed from 131.91 B INR to 115.18 B INR, representing a -12.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Mankind Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mankind Pharma

All Key Metrics — Mankind Pharma